Apoptotic eosinophils express IL-2R chains α and β and co-stimulatory molecules CD28 and CD86

Respiratory Medicine

Volumn 97, Issue 8, 2003, Pages 893-902

  Seton, Kristina ^a   Håkansson, Lena ^a   Carlson, Marie ^a   Stålenheim, Gunnemar ^a   Venge, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Apoptosis; CD122; CD25; CD28; CD86; Eosinophils; Flow cytometry; IL 2

Indexed keywords

ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CD28 ANTIGEN; CD86 ANTIGEN; CD9 ANTIGEN; CELL MARKER; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR BETA; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ALPHA CHAIN; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BETA CHAIN; CELL COMMUNICATION; CELL CULTURE; CELL FUNCTION; CELL SURFACE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOCYTE; MALE; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0041630700     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)00112-4     Document Type: Article

References (37)

1. Weller PF, Rand TH, Barrett T, Elovic A, Wong DTW, Finberg RW. Accessory cell function of human eosinophils: HLA-DR-dependent, MHC-restricted antigen-presentation and IL-1Alpha expression. J Immunol 1993;150:2554-62.
2. Handzel ZT, Busse WW, Sedgwick JB, Vrtis R, Lee WM, Kelly EAB, et al. Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol 1998;160:1279-84.
3. Rumi C, Rutella S, Bonini S, Lambiase A, Sica S, Puggioni P, et al. Immunophenotypic profile of peripheral blood eosinophils in acute graft-vs.-host disease. Exp Hematol 1998;26:170-8.
4. Riedel D, Lindemann A, Brach M, Mertelsmann R, Herrmann F. Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce surface expression of interleukin-2 receptor p55-chain and CD4 by human eosinophils. Immunology 1990;70:258-61.
5. Rodgers S, Rees RC, Hancock BW. Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin-2 (rhIL-2) therapy. Br J Haematol 1994;86:746-53.
6. Plumas J, Gruart V, Aldebert D, Truong MJ, Capron M, Capron A, et al. Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 interleukin 2 receptor subunit. Eur J Immunol 1991; 21:1265-70.
7. Rand TH, Silberstein DS, Kornfeld H, Weller PF. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 1991;88:825-32.
8. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993;73:5-8.
9. Lampinen M, Hakansson L, Venge P. Interleukin-2 inhibits eosinophil migration but is counteracted by IL-5 priming. Clin Exp Allergy 2001;31:249-58.
10. Celestin J, Rotschke O, Falk K, Ramesh N, Jabara H, Strominger J, et al. IL-3 induces B7.2 (CD86) expression and costimulatory activity in human eosinophils. J Immunol 2001;167:6097-104.
11. Woerly G, Roger N, Loiseau S, Dombrowicz D, Capron A, Capron M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (Interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J Exp Med 1999; 190:487-95.
12. Ueda Y, Levine BL, Huang ML, Freeman GJ, Nadler LM, June CH, et al. Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. Int Immunol 1995;7:957-66.
13. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995;2:523-32.
14. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995;81:979-82.
15. Ohkawara Y, Lim KG, Xing Z, Glibetic M, Nakano K, Dolovich J, et al. CD40 expression by human peripheral blood eosinophils. J Clin Invest 1996;97:1761-6.
16. Gauchat J-F, Henchoz S, Fattah D, Mazzei G, Aubry J-P, Jomotte T, et al. CD40 ligand is functionally expressed on human eosinophils. Eur J Immunol 1995;25:863-5.
17. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58:4-43.
18. Trulson A, Nilsson S, Venge P. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haemotol 1997;98:312-4.
19. Ishimitsu T, Torisu M. The role of eosinophils in interleukin-2/lymphokine-activated killer cell therapy. Surgery 1993;113:192-9.
20. Rivoltini L, Viggiano V, Spinazzè S, Santoro A, Colombo MP, Takatsu K, et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 2. Int J Cancer 1993;54:8-15.
21. Todd R, Donoff BR, Chiang T, Chou MY, Elovic A, Gallagher GT, et al. The eosinophil as a cellular source of transforming growth factor alpha in healing cutaneous wounds. Am J Pathol 1991;138:1307-13.
22. Dombrowicz D, Capron M. Eosinophils, allergy and parasites. Curr Opin Immunol 2001;13:716-20.
23. Wardlaw AJ. Eosinophils in the 1990s: new perspectives on their role in health and disease. Postgrad Med J 1994;70(826):536-52.
24. Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 2001;108:957-62.
25. Hansel TT, De Vries IJM, Iff T, Rihs S, Wandzilak M, Betz S, et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991;145:105-10.
26. Sandström K, Hakansson L, Lukinius A, Venge P. A method to study apoptosis in eosinophils by flow cytometry. J Immunol Methods 2000;240:55-68.
27. Capron M, Woerly G, Kayaba H, Loiseau S, Roger N, Dombrowicz D. Invited lecture: rote of membrane receptors in the release of t helper and cytokines by eosinophils. Int Arch Allergy Immunol 2001;124:223-6.
28. Hoyne GF, Tan K, Corsin-Jimenez M, Wahl K, Stewart M, Howie SE, et al. Immunological tolerance to inhaled antigen. Am J Respir Crit Care Med 2000;162:S169-74.
29. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816-22.
30. Simon HU. Delayed eosinophil apoptosis and its bearing on chronic allergic inflammation. Schweiz Med Wochenschr 1997;127:1743-7.
31. Woolley KL, Gibson PG, Carty K, Wilson AJ, Woolley MJ. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med 1996; 154:237-43.
32. Wedi B, Raap U, Lewrick H, Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997;100:536-43.
33. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, Barnes PJ. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 2000;106:77-83.
34. Evans DJ, Lindsay MA, O'Connor BJ, Barnes PJ. Priming of circulating human eosinophils following late response to allergen challenge. Eur Respir J 1996;9:703-8.
35. Walsh GM. Mechanisms of human eosinophil survival and apoptosis. Clin Exp Allergy 1997;27:482-7.
36. Ohta K, Yamashita N. Apoptosis of eosinophils and lymphocytes in allergic inflammation. J Allergy Clin Immunol 1999;104:14-21.
37. Greenfield EA, Howard E, Paradis T, Nguyen K, Benazzo F, McLean P, et al. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. J Immunol 1997;158:2025-34.